Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Savient Shares Fall as Medical Chief Resigns

By Pharmaceutical Processing | June 26, 2009

NEW YORK (AP) — Shares of Savient Pharmaceuticals Inc. fell Friday after the company said Chief Medical Officer Dr. Zebulun D. Horowitz resigned, marking another key executive to leave the company over the past 12 months. Shares fell 35 cents, or 2.5 percent, to $13.50 in midday trading. The stock has traded between $2.80 and $28.42 over the past 52 weeks. In November, President and CEO Christopher Clement resigned, and in February Chief Financial Officer Brian Hayden was “terminated.” The company did not provide details on those executive moves. In a Securities and Exchange Commission Filing late Thursday, it said Horowitz’s resignation was not due to any disagreement with the company and he left to pursue other interests. Savient is currently waiting for a FDA regulatory decision on the experimental gout drug Krystexxa. A panel of experts has already recommended the drug’s approval and the FDA normally follows the opinions of its advisers, though that is not a requirement. Leerink Swann analyst Joseph P. Schwartz reaffirmed an “Outperform” rating on the stock, saying the recent resignation doesn’t come as a surprise following the prior executive shifts. “The chief medical officer position has become somewhat extraneous since the board’s BLA (drug) Advisory Committee has been guiding Krystexxa through the FDA approval process,” he said, in a note to investors. He expects the stock value to hit $18 over the next 12 months and considers the company a potential buyout target because of Krystexxa’s potential.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE